The US Food and Drug Administration (FDA) has announced the launch of a new pilot programme. This programme aims to accelerate the review process for generic drugs. Companies research, develop, and manufacture these drugs entirely within the United States. The initiative aims to incentivise pharmaceutical companies to onshore their operations. It strengthens the domestic supply chain and reduces America’s heavy…
Tag: US manufacturing
-
Trump’s Tariff Stick Won’t Bring Generic Drug Manufacturing Home
President Donald Trump’s administration has championed Trump’s Tariff Stick as a means to compel global industries to relocate manufacturing to the United States. However, for the generic drug sector, which supplies roughly 90% of all medicines consumed by Americans, Trump’s Tariff Stick is a blunt instrument with potentially damaging outcomes. Industry leaders are cautioning that, instead of encouraging domestic production,…